Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 593-601

  Muratore, Claudio A ^a   Baranchuk, Adrian ^b  

^a HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^b KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Chronic chagasic cardiomyopathy; Emerging therapeutic options

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BENZNIDAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; NEUROHORMONE; PLACEBO; SPIRONOLACTONE; ANTIPARASITIC AGENT;

ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CELL THERAPY; CHAGAS DISEASE; CONGESTIVE HEART FAILURE; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG CONTRAINDICATION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE; HEART PACING; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEART VENTRICULOGRAPHY; HEMODYNAMICS; HORMONE ACTION; HUMAN; PATHOGENESIS; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEX RATIO; SICK SINUS SYNDROME; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT PLANNING; ARTIFICIAL HEART PACEMAKER;

ANTI-ARRHYTHMIA AGENTS; ANTIPARASITIC AGENTS; ARRHYTHMIAS, CARDIAC; CARDIAC RESYNCHRONIZATION THERAPY; CATHETER ABLATION; CHAGAS CARDIOMYOPATHY; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; PACEMAKER, ARTIFICIAL;

EID: 79952051819     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s8355     Document Type: Review

References (84)

1. World Health Organization. Control of Chagas' disease. Report of a WHO Expert Committee. Technical Report Series 811, Geneva, 1991.
2. Rosenbaum MB. Chagasic myocardiopathy. Prog Cardiovasc Dis. 1964;7:199-225.
3. El-Sayed NM, Myler PJ, Bartholomeu DC, et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science. 2005;309(5733):409-415.
4. Nunes MC, Barbosa MM, Ribeiro AL, Barbosa FB, Rocha MO. Ischemic cerebrovascular events in patients with Chagas cardiomyopathy: a prospective follow-up study. J Neurol Sci. 2009; 278(1-2):96-101.
5. Dias E, Laranja FS, Miranda A, Nobrega G. Chagas' disease: a clinical, epidemiologic and pathologic study. Circulation. 1956;14: 1035-1060.
6. Mota EA, Guimaraes AC, Santana OO, Sherlock I, Hoff R, Weller TH. A nine year prospective study of Chagas' disease in a defined rural population in northeast Brazil. Am J Trop Med Hyg. 1990; 42:429-440.
7. Aras R, de Matta JA, Mota G, Gomes I, Melo A. Cerebral infarction in autopsies of chagasic patients with heart failure. Arq Bras Cardiol. 2003;8:411-413.
8. Rassi A Jr, Rassi SG, Rassi A. Sudden death in Chagas' disease. Arq Bras Cardiol. 2001;76:75-96.
9. Baranchuk A, Rosas F, Morillo CA. Enfermedad de Chagas en Países Desarrollados: Mito o Realidad (Chagas' disease in developed countries: myth or reality). In F Rosas, D Vanegas, and M Cabrales (eds). Enfermedad de Chagas, Bogotá, Sociedad Colombiana de Cardiología, Sociedad Española de Cardiología; 2007; p. 217-219.
10. Roberti RR, Martinez EE, Andrade JL, et al. Chagas cardiomyopathy and captopril. Eur Heart J. 1992;13:966-970.
11. Szajnbok FE, Barretto AC, Mady C, et al. Beneficial effects of enalapril on the diastolic ventricular function in Chagas myocardiopathy. Arq Bras Cardiol. 1993;60:273-278.
12. Davila DF, Angel F, Arata DB, et al. Effects of metoprolol in chagasic patients with severe congestive heart failure. Int J Cardiol. 2002;85: 255-260.
13. Botoni FA, Poole-Wilson PA, Ribeiro AL, et al. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. Am Heart J. 2007;153:544-548.
14. Issa VS, Amaral AF, Cruz FD, et al. Beta-blocker therapy and mortality of patients with Chagas cardiomyopathy: a subanalysis of the REMADHE prospective trial. Circ Heart Fail. 2010;3:82-88.
15. Laranja FS, Dias E, Nobrega G, Miranda A. Chagas' disease. A clinical, epidemiologic and pathologic study. Circulation. 1956;14: 1035-1060.
16. Andrade ZA, Andrade SG, Oliveira G, Alonso DR. Histopathology of the conduction tissue of the heart in Chagas' myocarditis. Am Heart J. 1978;93:316-324.
17. Elizari MV, Chiale PA. Cardiac Arrhythmias in Chagas' heart disease. J Cardiovasc Electrophysiol. 1993;4:596-598.
18. Madoery C, Ruiz A, Martinez Rubio A, Madoery R. Signal-averaged electrocardiography in Chagas' disease. In: MC Tentori, L Segura, and DL Hayes (eds). Arrhythmia management in chagas' disease. New York: Futura Publishing Co. Inc., 2000: p. 67-82.
19. Rabinovich R, Muratore C, Baranchuk A Modo de inicio de las taquiarritmias ventriculares en la cardiopatía chagásica crónica. Arch Cardiol Mex. 2008;78(3):248-253.
20. Baruffa G. Contribuicao ao conhecimento da forma cronica da doenca de Chagas na zona sul do Rio Grande do Sul. R AMRIGS. 1974;18:237-250.
21. Aquatella H, Catalioti F, Gomez-Mancebo JR, et al. Long-term control of Chagas disease in Venezuela: effects on serologic findings, electrocardiographic abnormalities, and clinical outcome. Circulation. 1987;76:556-562.
22. Garzon SAC, Lorga AM, Jacob JLB, et al. Predictors of mortality in chronic Chagas heart disease long-term follow up of 987 subjects for up to 22 years. J Am Coll Cardiol. 1998;31:107C.
23. Rassi A Jr, Waktare JEP, Rassi SG, et al. Chagas heart disease: long term prognostic significance of nonsustained ventricular tachycardia and lef ventricular dysfunction. PACE. 1999;22:862.
24. Coura JR, Abreu LL, Pereira JB, Willcox HP. Morbidade da doen ̧ca de Chagas. IV Estudo longitudinal de dez anos em Pains e Iguatama, Minas Gerais, Brasil. Mem Inst Oswaldo Cruz. 1985;80:73-80.
25. Carrasco HA, Parada H, Guerrero L, Duque M, Duran D, Molina C. Prognostic implications of clinical, electrocardiographic and hemodynamic findings in chronic Chagas' disease. Int J Cardiol. 1994;43: 27-38.
26. De Paola AA, Gomes JA, Terzian AB, Myamoto MH, Martinez Filho E. Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J. 1995;74:293-295.
27. Haedo AH, Chiale PA, Bandieri JD, Lazzari JO, Elizari MV, Rosenbaum MB. Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms. J Am Coll Cardiol. 1986;7:1114-1120.
28. Rosenbaum M, Posse R, Sgammini H, et al. Comparative multicenter clinical study of flecainide and amiodarone in the treatment of ventricular arrhythmias associated with chronic Chagas cardiopathy. Arch Inst Cardiol Mex. 1987;573:25-330.
29. Chiale PA, Halpern MS, Nau GJ, et al. Efficacy of amiodarone during long-term treatment of malignant ventricular arrhythmias in patients with chronic chagasic myocarditis. Am Heart J. 1984;107:656-665.
30. Scanavacca MI, Sosa EA, Lee JH, Bellotti G, Pileggi F. Empiric therapy with amiodarone in patients with chronic Chagas cardiomyopathy and sustained ventricular tachycardia. Arq Bras Cardiol. 1990;54: 367-371.
31. Barbosa EC, Albanesi Filho FM, Ginefra P, et al. Evaluation of syncope in patients with chronic Chagas heart disease. Arq Bras Cardiol. 1991;57:301-305.
32. Sarabanda AV, Sosa E, Simões MV, Figueiredo GL, Pintya AO, Marin-Neto JA. Ventricular tachycardia in Chagas' disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms. Int J Cardiol. 2005;102(1):9-19.
33. Leite L, Fenelon G, Simoes A Jr, et al. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone and sotalol. J Cardiovasc Electrophysiol. 2003;14:567-573.
34. The Antiarrhythmics Versus Implantable Defibrillator (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576-1583.
35. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000;101:1297-1302.
36. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmia drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-754.
37. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl Med J. 2002;346:877-883.
38. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
39. Muratore C, Rabinovich R, Iglesias R, Gonzalez M, Darú V, Sosa Liprandi A. Implantable cardioverter defibrillators in patients with chagas disease: are they different from patients with coronary disease? PACE. 1997;20:194-197.
40. Cardinalli-Neto A, Greco O, Bestetti R. Automatic implantable cardioverter-defibrillators in chagas heart disease patients with malignant ventricular arrhythmias. PACE. 2006;29:467-470.
41. Cardinalli-Neto A, Bestetti R, Cordeiro J, Rodrigues V. Predictors of all-cause mortality for patients with chronic chagas heart disease receiving implantable cardioverter defibrillator therapy. J Cardiovasc Electrophysiol. 2007;18:1236-1240.
42. Muratore C, Batista Sa L, Chiale P, et al. Implantable cardioverter defibrillators and Chagas' disease: results of the ICD Registry Latin America. Europace. 2009;11(2):164-168.
43. Di Toro D, Muratore C, Aguinaga L, et al. Predictors of all-cause 1 year mortality for patients with chronic chagas' heart disease receiving implantable cardioverter defibrillator therapy in the ICD registry. (Abstract). Accepted for presentation Heart Rhythm Society 2010. 44.
44. Rabinovich R, Muratore C, Iglesias R, et al. Time to first shock in implantable cardioverter def ibrillator (ICD) patients with Chagas cardiomyopathy. Pacing Clin Electrophysiol. 1999; 22:202-205.
45. Greco OT, Ardito RV, Garzon SA, et al. Follow-up of 991 patients with multiprogrammable artificial cardiac pacemaker. Arq Bras Cardiol. 1987;49:327-331.
46. Vanegas Cadavid DI. Marcapassos na doença de chagas. Rev Latino Americana MCP y Arritmias. 2008;21:70-76.
47. Tentori C, Chirife R, Ruiz A, Mazzetti H, Styglicz E, Menendez C. Long-term evaluation of patients with chronic Chagas disease and implanted cardiac pacemaker. (Abstract). Accepted for presentation Cardiostim 2010 (in press).
48. Garcia Rincon L, Costa Rocha M, Baccarini Piris M, et al. Perfil clínico de pacientes chagásicos e não-chagásicos portadores de marca-passo cardíaco artificial. Rev Soc Bras Med Trop. 2006;39(3):245-249.
49. Costa R, Rassi A, Leao M. Estudo clínico e epidemiológico de pacientes submetidos a implante de marcapasso cardíaco artificial permanente: comparação dos portadores da doença de Chagas com os de doenças degenerativas do sistema de condução. Rev Bras Cir Cardiovasc. 2004; 19(2):107-114.
50. d'Avila A, Splinter R, Svenson RH, et al. Chagas' disease: experimental evidence of the efficacy of near infrared lasers for catheter ablation of Chagas' VT. J Interv Card Electrophysiol. 2002;7(1):23-38.
51. Rosas F, Velasco V, Arboleda F, et al. Catheter ablation of ventricular tachycardia in Chagasic cardiomyopathy. Clin Cardiol. 1997;20(2): 169-174.
52. Sosa E, Scanavacca M, D'Avila A, Bellotti G, Pilleggi F. Radiofrequency catheter ablation of ventricular tachycardia guided by nonsurgical epicardial mapping in chronic Chagasic heart disease. Pacing Clin Electrophysiol. 1999;22:128-130.
53. Henz BD, do Nascimento TA, Dietrich C, et al. Simultaneous epicardial and endocardial substrate mapping and radiofrequency catheter ablation as first-line treatment for ventricular tachycardia and frequent ICD shocks in chronic chagasic cardiomyopathy. J Interv Card Electrophysiol. 2009;26(3):195-205.
54. Scanavacca M, Sosa E, d'Avila A, De Lourdes Higuchi M. Radiofrequency ablation of sustained ventricular tachycardia related to the mitral isthmus in Chagas' disease. Pacing Clin Electrophysiol. 2002;25(3):368-371.
55. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007;357: 2657-2665.
56. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985-1990.
57. Abraham WT, Young JB, León AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-2868.
58. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140-2150.
59. Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-1549.
60. Epstein A, DiMarco J, Ellenbogen K, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117:e350-e408.
61. Upadhyay G, Choudhry N, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation. J Am Coll Cardiol. 2008;52: 1239-1246.
62. Alves Fagundes A, Latado Braga A, Pereira Magalhaes L, et al. Impacto da terapia de ressincronizacao cardíaca na cardiopatía chagásica. Rev Latino Americana MCP y Arritmias. 2009;22(4):243.
63. Vilas-Boas F, Feitosa GS, Soares MB, et al. Early results of bone marrow cell transplantation to the myocardium of patients with heart failure due to Chagas disease. Arq Bras Cardiol. 2006;87:159-166.
64. Trainini JC, Barisani JL, Lago N, et al. Resultados alejados del implante miocárdico de células madre en la miocardiopatía chagásica Rev. Argent. Cardiol. 2007;75:257-263.
65. Clinical Trials. Cell therapy in Changes cardiomyopathy. 2010. Available from: http//www.clinicaltrials.gov/ct2/show/NCT00349271. Accessed on May 1, 2010.
66. Caldas IS, Talvani A, Caldas S, et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res. 2008;103(2):413-421.
67. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV. Pathogenesis of chronic chagas heart disease. Circulation. 2007;115:1109-1123.
68. Garcia S, Ramos CO, Senra JFV, et al. Treatment with benznidazole during the chronic phase of experimental chagas' disease decreases cardiac alterations. Antimicrob Agents and Chemother. 2005;49:1521-1528.
69. Marin-Neto JA, Rassi A Jr, Morillo CA, et al; BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J. 2008;156(1):37-43.
70. Personal communication (Dr. Carlos A. Morillo), Jan 9th, 2010.
71. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-2667.
72. Mehra NR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates 2006. J Heart Lung Transplant. 2006;25:1024-1042.
73. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831-836.
74. Wilson JR, Schwartz JS, St John Sutton M, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol. 1983;2:403-410.
75. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525-531.
76. Bertolino ND, Villafanha DF, Cardinalli-Neto A, et al. Prognostic impact of Chagas' disease in patients awaiting heart transplantation. J Heart Lung Transplant. 2010;29(4):449-453.
77. Mady C, Cardoso RH, Barreto AC, et al. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. Circulation. 1994;90:3098-3102.
78. Dib JA, Bestetti RB, Freitas PF, et al. Predictors of all-cause mortality for patients with Chagas' cardiomyopathy listed for heart transplantation. Int J Cardiol. 2009;136(2):162-164.
79. Bocchi EA, Fiorelli A. The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi. Ann Thorac Surg. 2001;71:1833-1838.
80. Campos SV, Strabelli TM, Amato Neto V, et al. Risk factors for Chagas' disease reactivation after heart transplantation. J Heart Lung Transplant. 2008;27(6):597-602.
81. Godoy HL, Guerra CM, Viegas RF, et al. Infections in heart transplant recipients in Brazil: the challenge of Chagas' disease. J Heart Lung Transplant. 2010;29(3):286-290.
82. Bocchi EA, Bellotti G, Mocelin A, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg. 1996;61:1727-1733.
83. Carvalho VB, Souza EFL, Vila JHA, et al. Transplantation in Chagas' disease: 10 years after the initial experience. Circulation, 1996;94: 1815-1817.
84. Almeida DR, Carvalho ACC, Branco JN, et al. Chagas disease reactivation after heart transplantation: efficacy of allopurinol treatment. J Heart Lung Transplant. 1996;15:988-992.